DUK
62
-2
AIZ
59
-5
PH
66
3
PDCO
60
2
IVZ
52
2
BBY
51
2
AME
48
-12
LRCX
77
2
CA
32
-4
WFC
65
7
NAVI
41
6
HAL
39
-9
EXPD
53
-5
CMS
61
-3
JBHT
49
6
JPM
66
2
APH
65
-2
KEY
50
7
CMCSA
52
3
PNC
48
6
DUK
62
-2
AIZ
59
-5
PH
66
3
PDCO
60
2
IVZ
52
2
BBY
51
2
AME
48
-12
LRCX
77
2
CA
32
-4
WFC
65
7
NAVI
41
6
HAL
39
-9
EXPD
53
-5
CMS
61
-3
JBHT
49
6
JPM
66
2
APH
65
-2
KEY
50
7
CMCSA
52
3
PNC
48
6
Financhill
Back

LakeShore Biopharma 10K Form

Sell
14

LSB
LakeShore Biopharma

Last Price:
0.61
Seasonality Move:
-22.53%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LSB News And Ratings

See the #1 stock for the next 7 days that we like better than LSB

LSB Financial Statistics

Sales & Book Value

Annual Sales: $100.37M
Cash Flow: $-23.41M
Price / Cash Flow: 0
Annual Sales: $0.82
Price / Book: 0.79

Profitability

EPS (TTM): -0.39800
Net Income (TTM): $-26.16M
Gross Margin: $77.97M
Return on Equity: 0%
Return on Assets: -11.69%

LakeShore Biopharma Earnings Forecast

Key LakeShore Biopharma Financial Ratios

  • The Gross Profit Margin over the past 3 years for LSB is 77.68%.
  • The Selling, General & Administrative Expenses for LSB have been equal to 48.50% of Gross Profit Margin.
  • The Research & Development expenses have been 46.38% of Revenue.
  • The Interest Expense is -21.21% of Operating Income.
  • The Net Earning history of LSB is -21.17% of Total Revenues.
  • Per Share Earnings over the last 3 years have been positive in 0 years.

LakeShore Biopharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: LSB
Website: yishengbio.com

Debt

Debt-to-Equity Ratio: 0.98
Current Ratio: 1.41
Quick Ratio: 1.04

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

LSB Technical Analysis vs Fundamental Analysis

Sell
14
LakeShore Biopharma (LSB) is a Sell

Is LakeShore Biopharma a Buy or a Sell?